ACC 2022: Triple Therapy - When to Use and How Long

ACC 2022 Conference Coverage

D. Kumbhani

Management of AF patients with ACS

Lankenau

P. Kowey, D. Ice

Five Things Every Internist Should Know About Anticoagulants

McMaster University Department of Medicine

S. Mithoowani

ACP 2024 Insights: Acute Coronary Syndromes - Evaluation, Diagnosis …

Insights from 2024 ACP Annual Meeting

D. Berg

Treating Stenosis or Ischemia Does Not Improve Outcomes: Medical The…

Cedars Sinai

W. Boden

Therapy Post PCI: What Is the Rationale for DAPT and OAC? When to Us…

Complex Coronary Cases

U. Baber

Peri-Operative Management of Anticoagulation

Icahn School of Medicine at Mount Sinai

A. Dunn

Aspirin for Primary Prevention

Salim Virani

Anticoagulation in ECLS - To Bleed, or Not to Clot...

UCLA Health

A. Young

Stable CAD: ASA Alone, Prolonged DAPT or Low-Dose Rivaroxaban?

Canadian Collaborative Research Network

M. Sabatine

AHA 2022 Debate: Should CABG Be Level IIB for Improving Survival Com…

AHA 2022 Conference Coverage

F. Bakaeen

Dual Pathway Inhibition in the Cardiometabolic Patient: How Effectiv…

Cardiometabolic Health Congress (CMHC)

D. Bhatt

AHA 2022: Bivalirudin With a Post-PCI High-Dose Infusion versus Hepa…

AHA 2022 Conference Coverage

G. W. Stone

Left Ventricular Thrombosis: An Overview

Houston Methodist DeBakey Heart and Vascular Center

Y. Saleh

What is the Optimal DAPT Duration?

Scottsdale Interventional Forum 2018

R. Yeh

TCT 2023 Insights: Where Do Antithrombotics Fit In?

TCT 2023 Insights

M. Bonaca

Eliquis: Alternative Anticoagulation for HeartMate 3 Ventricular Ass…

Cedars Sinai

M. Slaughter

PAD in Patients with (a Risk of) Cardiometabolic Disease: What Is th…

Cardiometabolic Health Congress (CMHC)

D. Bhatt

PCI Pharmacology in 2015: Choosing the Right Antiplatelet & Anticoag…

Scottsdale Interventional Forum 2015

S. Bailey

STEMI in the COVID Era: Should You Use Thrombolytic Therapy or Prima…

7th Annual Western New England Acute Cardiology Conference

D. Fisher